The LYCRA Company Showcases Denim Innovations at Kingpins New York
18.7.2022 12:00:00 EEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the apparel and personal care industries, is exhibiting its latest products for denim in person at Kingpins New York July 20-21 at Pier 36 in New York City. The company is showcasing samples made with LYCRA® ADAPTIV fiber, LYCRA® DUAL COMFORT technology, and its other industry-leading denim fibers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220718005067/en/
The LYCRA Company showcases denim innovations at Kingpins NYC. (Photo: Business Wire)
LYCRA® ADAPTIV fiber is a patent-pending revolutionary fiber that creates "one-size-fits-more" garments that adapt to fit different body shapes within a size. It also delivers a second-skin effect with excellent recovery and comfortable holding power.
"Consumers have different body types and this can impact garment fit and comfort," said Rita Ratskoff, senior strategic manager - denim, The LYCRA Company. "By offering greater shape tolerance, LYCRA® ADAPTIV fiber has the potential to reduce apparel returns and manufacturing waste by enabling the undercutting of patterns."
LYCRA® DUAL COMFORT technology combines the comfortable fit of stretch fabrics, the cool and dry comfort of moisture management, and LYCRA® T400® A EcoMade fiber, made from 68% sustainable resources including recycled and renewable content.
In The LYCRA Company booth, show visitors can also find innovative denim solutions from the LYCRA® XTRA LIFE™ brand's family of innovative denim solutions, including LYCRA® Anti-Slip fiber, LYCRA® dualFX® technology, and LYCRA® T400® fiber. They create long-lasting, durable garments that enable designers to develop heavy wash downs and distressed looks without fear.
For garment makers seeking sustainable offerings that reduce waste, denim that uses recycled materials will be on display. LYCRA® EcoMade fiber contains 20 percent recycled content, and COOLMAX® and THERMOLITE® EcoMade technologies are made from 100% textile waste.
"The LYCRA Company is committed to developing an innovative range of sustainable solutions made with renewable and recycled content that will enhance the performance of our customers' offerings while minimizing their environmental impact," said Jean Hegedus, sustainability director, The LYCRA Company. "We are excited to be in person at Kingpins again to promote our sustainable denim fibers that help reduce waste and set the stage for circularity."
Hegedus will join a panel discussion at Kingpins on July 21 at 11:30 a.m. entitled, "In Conversation: Denim Changemakers." This panel brings together representatives from companies in the United Nations Conscious Fashion and Lifestyle Network, whose members are accelerating change in the denim sector. Participants will discuss industry commitments to increase sustainable practices and advance collective action to reach the United Nations' Sustainable Development Goals.
Kingpins New York is an invitation-only event for the denim community at Pier 36 / Basketball City in Manhattan. For more information, visit kingpinsshow.com/shows/new-york/.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com.
LYCRA®, dualFX®, T400®, XTRA LIFE™, COOLMAX® and THERMOLITE® are trademarks of The LYCRA Company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005067/en/
Contact information
Kristin Altimari
kristin.altimari@lycra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom